Clavis Pharma elects Robert Spiegel to board
This article was originally published in Scrip
Clavis Pharma, a Norwegian cancer drug development company, has elected Dr Robert Spiegel to its board of directors. Dr Spiegel worked at Schering-Plough for 25 years in various roles including senior vice-president of clinical research and chief medical officer. He also serves on the boards of Geron Corporation, Capstone Therapeutics and Talon Therapeutics.